Search

Displaying results 851 - 860 of 7498 in total
  1. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005 … It is prepared by the reaction of gluconic acid solutions with cupric oxide or basic cupric carbonate.

    Mixtures: Super Daily No 2
  2. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference.

  3. Drug

    Gallamine triethiodide

    go.drugbank.com/drugs/DB00483
    ApprovedWithdrawn

    The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac … It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)

  4. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor

  5. Drug

    Metacycline

    go.drugbank.com/drugs/DB00931
    Approved

    A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.

  6. Drug

    Benzquinamide

    go.drugbank.com/drugs/DB00767
    ApprovedWithdrawn

    The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

  7. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.

  8. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. … Currently dehydroascorbic acid is an experimental drug with no known approved indications.

  9. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).

  10. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_. … [A230348] Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated